Clinical trial
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Study Evaluating the Safety and Efficacy of Simufilam 100 mg Tablets in Subjects With Mild-to-Moderate Alzheimer's Disease
NCT04994483 is registered in ClinicalTrials.gov with Cassava Sciences, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Study Evaluating the Safety and Efficacy of Simufilam 100 mg Tablets in Subjects With Mild-to-Moderate Alzheimer's Disease
- Lead sponsor
- Cassava Sciences, Inc.
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- November 3, 2021
- Completion date
- October 2, 2024
- Enrollment
- 804 (actual)
- Sites
- 88
Conditions
As the registry lists them; a condition with its own page is linked.